Keeping it simple: Genetics referrals for all invasive serous ovarian cancers

Gynecologic Oncology

Volumn 130, Issue 2, 2013, Pages 329-333

  Demsky, R ^a,b   McCuaig, J ^a   Maganti, M ^d   Murphy, K J ^a,c   Rosen, B ^a,c   Armel, S R ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Ovarian cancer Serous BRCA1 BRCA2 Genetic testing Genetic counseling

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANADA; CANCER GENETICS; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEALTH PROGRAM; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; TUMOR INVASION;

BRCA1; BRCA2; GENETIC COUNSELING; GENETIC TESTING; OVARIAN CANCER; SEROUS;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OVARIAN NEOPLASMS; REFERRAL AND CONSULTATION;

EID: 84880298290     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.05.003     Document Type: Article

References (31)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics Canadian Cancer Statistics 2012 2012 Canadian Cancer Society Toronto
2. American Cancer Society Cancer Facts & Figures 2012 2012 American Cancer Society Atlanta
3. E. Claus, J. Schildkraut, W. Thompson, and N. Risch The genetic attributable risk of breast and ovarian cancer Cancer 77 11 1996 2318
4. S. Rubin, M. Blackwood, C. Bandera, K. Behbakht, I. Benjamin, and T. Rebbeck BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing Am J Obstet Gynecol 178 4 1998 670
5. T. Pal, J. Permuth-Wey, J. Betts, J. Krischer, J. Fiorica, and H. Arango BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 12 2005 2807
6. H. Risch, J. McLaughlin, D. Cole, B. Rosen, L. Bradley, and E. Kwan Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 68 3 2001 700
7. A. Rodríguez, M. Llacuachaqui, G. Pardo, R. Royer, G. Larson, and J. Weitzel BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia Gynecol Oncol 124 2 2012 236
8. S. Zhang, R. Royer, S. Li, J. McLaughlin, B. Rosen, and H. Risch Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer Gynecol Oncol 121 2 2011 353
9. K. Alsop, S. Fereday, C. Meldrum, A. deFazio, C. Emmanuel, and J. George BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J Clin Oncol 30 21 2012 2654
10. D. Vicus, A. Finch, I. Cass, B. Rosen, J. Murphy, and I. Fan Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube Gynecol Oncol 118 3 2010 299
11. G. Hirsh-Yechezkel, A. Chetrit, F. Lubin, E. Friedman, T. Peretz, and R. Gershoni Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel Gynecol Oncol 89 3 2003 494
12. H. Risch, J. McLaughlin, D. Cole, B. Rosen, L. Bradley, and I. Fan Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada J Natl Cancer Inst 98 23 2006 1694
13. K. Scrader, J. Hurlburt, S. Kalloger, S. Hansford, S. Young, and D. Huntsman Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy Obstet Gynecol 120 2 2012 235
14. American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins Gynecology, ACOG Committee on Genetics, and Society of Gynecologic Oncologists ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome Obstet Gynecol 113 4 2009 957
15. J. Berliner, and A. Fay Practice Issues Subcommittee of the National Society of Genetic Counselors' Familial Cancer Risk Counseling Special Interest Group. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors J Genet Couns 16 3 2007 241 260
16. National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian version 1 [Internet] [cited 2012 Oct 10]. Available from http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf 2012
17. J.S. Kwon, M.S. Daniels, C.C. Sun, and K.H. Lu Preventing future cancers by testing women with ovarian cancer for BRCA mutations J Clin Oncol 28 4 2010 675
18. A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer J Clin Oncol 26 1 2008 20
19. P. Fong, T. Yap, D. Boss, C. Carden, M. Mergui-Roelvink, and C. Gourley Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 15 2010 2512
20. K. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, and K. Tonkin Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol 12 9 2011 852
21. A. Tutt, M. Robson, J. Garber, S. Domchek, M. Audeh, and J. Weitzel Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 9737 2010 235 244
22. American College of Medical Genetics with Support from the New York State Department of Health Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines [Internet] [cited 2012 Oct 25]. Available from: http://www.health.ny.gov/diseases/cancer/obcancer/contents.htm
23. J. Lancaster, C. Powell, N. Kauff, I. Cass, L. Chen, and K. Lu Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions Gynecol Oncol 107 2 2007 159
24. H. Nelson, L. Huffman, R. Fu, and E. Harris U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force Ann Intern Med 143 3 2005 362
25. A. Antoniou, P. Pharoah, S. Narod, H. Risch, J. Eyfjord, and J. Hopper Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 5 2003 1117
26. S. Chen, and G. Parmigiani Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 11 2007 1329
27. A. Lanceley, Z. Eagle, G. Ogden, S. Gessler, K. Razvi, and J.A. Ledermann Family history and women with ovarian cancer: is it asked and does it matter?: An observational study Int J Gynecol Cancer 22 2 2012 254
28. K. Metcalfe, I. Fan, J. McLaughlin, H. Risch, B. Rosen, and J. Murphy Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study Gynecol Oncol 112 1 2009 68
29. R. Lacour, M. Daniels, S. Westin, L. Meyer, C. Burke, and K. Burns What women with ovarian cancer think and know about genetic testing Gynecol Oncol 111 1 2008 132
30. B. Meiser, M. Gleeson, N. Kasparian, K. Barlow-Stewart, M. Ryan, and K. Watts There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer Gynecol Oncol 124 1 2012 153 157
31. L.A. Meyer, M.E. Anderson, R.A. Lacour, A. Suri, M.S. Daniels, and D.L. Urbauer Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities Obstet Gynecol 115 5 2010 945